KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Short-term Investments: 2014-2025

Historic Short-term Investments for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Sep 2025 value amounting to $278.6 million.

  • Aurinia Pharmaceuticals' Short-term Investments fell 10.59% to $278.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $278.6 million, marking a year-over-year decrease of 10.59%. This contributed to the annual value of $275.0 million for FY2024, which is 8.81% down from last year.
  • Aurinia Pharmaceuticals' Short-term Investments amounted to $278.6 million in Q3 2025, which was up 6.29% from $262.1 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' 5-year Short-term Investments high stood at $311.6 million for Q3 2024, and its period low was $191.7 million during Q1 2021.
  • Its 3-year average for Short-term Investments is $278.3 million, with a median of $275.0 million in 2024.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Short-term Investments skyrocketed by 1,709.17% in 2021, and later fell by 11.76% in 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' Short-term Investments (Quarterly) stood at $234.2 million in 2021, then increased by 26.07% to $295.2 million in 2022, then climbed by 2.17% to $301.6 million in 2023, then decreased by 8.81% to $275.0 million in 2024, then fell by 10.59% to $278.6 million in 2025.
  • Its last three reported values are $278.6 million in Q3 2025, $262.1 million for Q2 2025, and $246.5 million during Q1 2025.